Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07365670 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)

Study acronym: COMPAXE-HNF
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Apr 5, 2029 → Nov 2029
See other at-risk trials from Centre Hospitalier Universitaire de la Réunion

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Apr 5, 2029 to Nov 2029 Show 5 more changesShow less
    • Start date: Apr 1, 2026 to Nov 2026
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 3 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to compare the accuracy of two different blood sampling methods from a central venous catheter (CVC) for measuring anti-Xa activity in children receiving unfractionated heparin (UFH) from this CVC. The results will be compared to a "gold standard" sample taken from an arterial catheter (KTA) whithout UFH. The objective is to identify a more reliable method for monitoring UFH, thereby reducing the risk of bleeding or thrombosis in these patients.
Trial Details
NCT Number NCT07365670
Lead Sponsor Centre Hospitalier Universitaire de la Réunion
Conditions
(from sponsor)		 Congenital Heart Disease, Unfractionated Heparin, Anti Xa Activity
Related terms Heart Defects, Congenital, Thrombosis
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov